1. Shin, DY, Na, II, Kin, CH, et al. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 2014; 9: 195–199.
Google Scholar | Crossref | Medline2. Ballard, P, Yates, JWT, Yang, Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016; 22: 5130–5140.
Google Scholar | Crossref | Medline3. Soria, JC, Ohe, Y, Vansteenkiste, J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med 2018; 378: 113–125.
Google Scholar | Crossref | Medline4. Reungwetwattana, T, Nakagawa, K, Cho, BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non–small-cell lung cancer. J Clin Oncol 2018; 36: 3290–3297.
Google Scholar | Crossref5. Cheng, H, Perez-Soler, R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol 2018; 19: e43–e55.
Google Scholar | Crossref | Medline6. Goss, G, Tsai, CM, Shepherd, FA, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol 2018; 29: 687–693.
Google Scholar | Crossref | Medline7. Wu, YL, Ahn, MJ, Garassino, MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol 2018; 36: 2702–2709.
Google Scholar | Crossref | Medline8. Katayama, T, Shimizu, J, Suda, K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009; 4: 1415–1419.
Google Scholar | Crossref | Medline9. Lee, E, Keam, B, Kim, DW, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non–small-cell lung cancer. J Thorac Oncol 2013; 8: 1069–1074.
Google Scholar | Crossref | Medline10. Yang, JCH, Kim, S-W, Kim, D-W, et al. Osimertinib in patients with epidermal growth factor receptor mutaion-positive non-small cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol 2020; 38: 538–547.
Google Scholar | Crossref | Medline11. Park, S, Lee, MH, Seong, M, et al. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol 2020; 31: 1397–1404.
Google Scholar | Crossref | Medline12. Qin, K, Hou, H, Zhang, X. Prognostic value of TP53 concurrent mutations for EGFR-TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. BMC Cancer 2020; 20: 328.
Google Scholar | Crossref | Medline